DiscoveRx® is a fast growing innovative company that develops, manufactures, and commercializes reagents and complete assay kits for the drug discovery and screening markets. Our products, biochemical and cell-based assays, enable customers to improve research productivity and effectiveness, thus accelerating the discovery and development of new drugs.

Business Overview
Founded in 2000, DiscoveRx is a privately held, venture-backed company headquartered in California with offices in England, Germany, and France. DiscoveRx is dedicated to the development and commercialization of innovative solutions to study major drug target classes such as GPCRs and kinases.

Proven Technology
DiscoveRx assay solutions are based on our core proprietary Enzyme Fragment Complementation (EFC) technology that is well established in clinical diagnostics and now further enhanced to provide unique solutions to drug discovery research.   EFC technology is a proven, established screening technology in most major pharmaceutical companies and our EFC-based HitHunter™ cAMP assays are the market leader in GPCR screening applications.  PathHunter™ technology, an adaptation of EFC technology, is an innovative and comprehensive assay system that enables in vivo cell-based assays for pathway profiling and screening.  Through our core HitHunter™, PathHunter™, and EFC technologies, DiscoveRx is able to offer assay solutions for every major class of drug target, including GPCRs, kinases, proteases, nuclear hormone receptors, transcription factors, and secreted proteins.

Corporate Partnerships
DiscoveRx remains committed to fully exploit the commercial potential of its EFC technology either solely or with its corporate partners. DiscoveRx has recently expanded its partnership with a leading life sciences organization GE Healthcare that allows a global market access to HitHunter products.

DiscoveRx values such patnerships and is actively seeking additional collaborative alliances to commercialize and provide early access to new technology platforms in the drug discovery and development markets.